Novavax reported $20.94M in Operating Profit for its fiscal quarter ending in December of 2025.





Operating Profit Change Date
Adma Biologics USD 52.44M 2.15M Jun/2026
Agenus USD 15.05M 656K Mar/2026
AstraZeneca USD 4.66B 1.5B Sep/2026
BioCryst Pharmaceuticals USD 98.46M 161.92M Jun/2026
Cassava Sciences USD -9.39M 1.78M Jun/2026
Geron USD 5.73M 18.38M Sep/2026
GlaxoSmithKline GBP 2.86B 251M Sep/2026
MannKind USD -59.44M 8.79M Sep/2026
Merck USD 7.33B 6.49B Sep/2026
Minerva Neurosciences USD -21.85M 17.48M Dec/2024
Moderna USD 130M 945M Sep/2026
Novartis USD 1.84B 2.39B Sep/2026
Novavax USD 20.94M 100.32M Dec/2025
Pfizer USD 662M 5M Sep/2026
Sanofi EUR 4.72B 2.34B Sep/2026
Sarepta Therapeutics USD -9.04M 22.33M Sep/2026
TG Therapeutics USD 85.9M 64.22M Sep/2026